Related Experiment Videos
Polyoxin D inhibits growth of zoopathogenic fungi
Abstract:
We demonstrated that polyoxin D at millimolar concentrations caused marked morphological alterations of the human pathogens Candida albicans and Cryptococcus neoformans. C. albicans incubated in the presence of this drug grew in long chains that were severely swollen. Polyoxin D inhibited the growth of C. neoformans and killed cells of both the yeast and the hyphal phase of C. albicans. These observations give the first evidence that polyoxin antibiotics can kill zoopathogenic fungi.
Insights
Polyoxin D, an antibiotic, significantly alters the morphology of human fungal pathogens Candida albicans and Cryptococcus neoformans. This study provides the first evidence that polyoxin antibiotics can effectively kill zoopathogenic fungi.
Area of Science:
- Medical Mycology
- Antimicrobial Drug Discovery
Background:
- Candida albicans and Cryptococcus neoformans are significant human fungal pathogens.
- The need for novel antifungal agents is critical due to rising resistance.
Purpose of the Study:
- To investigate the effects of polyoxin D on the morphology and viability of C. albicans and C. neoformans.
- To determine if polyoxin D exhibits antifungal activity against zoopathogenic fungi.
Main Methods:
- Exposure of C. albicans and C. neoformans to millimolar concentrations of polyoxin D.
- Microscopic observation of morphological changes.
- Assessment of fungal growth inhibition and cell viability.
Main Results:
- Polyoxin D induced marked morphological alterations in both C. albicans and C. neoformans.
- C. albicans exhibited growth in long, swollen chains.
- Polyoxin D inhibited C. neoformans growth and killed both yeast and hyphal forms of C. albicans.
Conclusions:
- Polyoxin D demonstrates significant antifungal activity against key human pathogens.
- This research presents the first evidence of polyoxin antibiotics possessing the ability to kill zoopathogenic fungi.
- Polyoxin D represents a potential candidate for novel antifungal therapies.